U.S. markets closed

Kancera AB (publ) (KAN.ST)

Stockholm - Stockholm Real Time Price. Currency in SEK
3.4250+0.0250 (+0.74%)
At close: 05:29PM CEST

Kancera AB (publ)

Karolinska Institutet Science Park
Nanna Svartz Väg 4
Solna 171 65
46 8 50 12 60 80

Full Time Employees5

Key Executives

NameTitlePayExercisedYear Born
Dr. Thomas Olin Ph.D.CEO & Director3.57MN/A1958
Mr. Hans RichterChief Financial OfficerN/AN/A1949
Dr. Martin NorinChief Operating OfficerN/AN/A1959
Mr. Peter SelinExec. VP of Corp. Devel.N/AN/A1973
Dr. Niclas BrynneHead of Clinical Devel.N/AN/A1961
Dr. Torbjörn LundströmChief Medical OfficerN/AN/A1953
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.


Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops HDAC for the treatment of nerve inflammation and pain; and ROR1 inhibitors for the treatment of solid tumors and blood cancers. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.

Corporate Governance

Kancera AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.